Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What's At Stake: Biopharma Profit Growth Reliant On Price Increases

Executive Summary

Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.

Advertisement

Related Content

List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma
Drugs' Net Price Only Growing Modestly, Express Scripts Finds
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel